Abstract. Experimental autoimmune encephalomyelitis (EAE) is an autoimmune disease mediated by CD4⁺ T cells. It is characterized by mononuclear cell infiltration around the small blood vessels in the central nervous system (CNS). Previous investigations have found that apoptosis is associated with the occurrence and development of autoimmune disease, and that mononuclear cell apoptosis and clearance from the CNS is one of the repair mechanisms of EAE. *Tripterygium wilfordii* glycoside (TWP) is an organic matter isolated from *Tripterygium wilfordii*, which has anti-inflammatory and immunosuppressive effects. In the present study, male Lewis rats were randomly divided into a normal control, EAE and TWP groups. Rats in EAE and TWP groups received injections of emulsified EAE antigen (myelin protein) at two points on the footpad while control group received PBS. The TWP group was then treated with TWP daily for 21 days. Symptoms and nerve function scores were observed and evaluated. Specimens of blood, brain and spinal cord were collected for further pathological examination, Tunel assay, ELISA and immunohistochemistry were performed to examine the effect of TWP on the onset of EAE, and changes in CNS inflammatory infiltration, cell apoptosis, and the expression of nuclear factor (NF) -κB P65 and interleukin (IL)-2. The results showed that the TWP treatment group exhibited decreased EAE and delayed onset, compared with the control. The clinical symptoms were significantly reduced and alleviation of inflammatory cell infiltration was observed. Compared with the EAE group, a higher inflammatory cell apoptotic rate, and reduced serum levels of IL-2 and NF-κB p65-positive cells were observed in the TWP treatment group. Therefore, TWP effectively inhibited EAE via the inhibition of CNS inflammatory cell infiltration, enhancement of inflammatory cell apoptosis, and downregulation of the expression of NF-κB and IL-2.

Introduction

Experimental autoimmune encephalomyelitis (EAE) is an autoimmune disease mediated by CD4⁺ T cells. It is used as a classical experimental animal model for the investigation of multiple sclerosis (MS) as it has similar features in terms of clinical manifestation, pathological characteristics and immune abnormalities (1). Previous studies have shown that apoptosis is closely associated with the occurrence, development and prognosis of autoimmune disease. The reduction of infiltrated mononuclear cells from the CNS in the form of apoptosis is one of the repair mechanisms of EAE (2). *Tripterygium wilfordii* belongs to the celastraceae family of plants, and exhibits anti-inflammatory, immunosuppressive and antitumor effects. *Tripterygium wilfordii* glycoside (TWP) is isolated from the *Tripterygium wilfordii* using organic solvent (3). Several effective ingredients of *Tripterygium wilfordii* have been widely used clinically for rheumatoid arthritis, systemic lupus erythematosus, and nephrotic syndrome, which have demonstrated beneficial effects (4). Several experiments have confirmed that *Tripterygium wilfordii* can inhibit lymphocyte proliferation through inducing T cell apoptosis (5). The present study established an EAE model using Lewis rats, examined the therapeutic effect of TWP on EAE and determined its possible mechanism. This may provide a valuable theoretical basis for the clinical application of TWP in the treatment of MS.

Materials and methods

Experimental animals. A total of 30 male Lewis rats, aged 6-8 weeks old and weighing 150-180 g, were provided by Shanghai Shiper Shall Kay Laboratory Animal Co., Ltd. (Shanghai, China; license no. SCXK 2008-001). The animals were fed in the laboratory of the Animal Center of Fujian Medical University (Fujian, China) and randomly divided into a normal control group (n=10), model group (EAE; n=10) and TWP treatment group (TWP; n=10). The rats were housed separately at room temperature, 50-65% humidity, on a 12-h light/dark cycle and were given access to water and food.
ad libitum. The study was approved by the Ethics Committee of Fujian Medical University (Fujian, China).

**Instruments and reagents.** The surgical instruments, homogenizer, mortar, infusion needle and Freund's complete adjuvant were provided by Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). The pertussis vaccine (BPV) was purchased from the Shanghai Institute of Biological Products of the Ministry of Health (Shanghai, China; 1 ml containing ~2×10^9 bacteria). An in situ apoptosis detection kit was purchased from Roche Diagnostics (Basel, Switzerland). Proteinase K and BCP/NBT developing solution were provided by Beijing Huamei Biological Engineering Company (Beijing, China). Nuclear solid red dye solution was provided by Fuzhou New Biotechnology Company (Fuzhou, China). Rabbit anti-rat NF-kB p65 antibody was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). The SABC kit was from Wuhan Boster Biotechnology, Ltd. (Wuhan, China). The IL-2 ELISA kit (K4800-100) was from Abnova (Taipei, Taiwan). TWP (10 mg/section; batch no. 101003) was produced by Fujian Huitian Biological Pharmaceutical Co., Ltd. (Fujian, China).

**Animal model preparation.** Myelin protein (MBP; 0.5 mg) was dissolved in 2 ml of 0.1 mol/l PBS solution, and then mixed with 2 ml Freund's complete adjuvant to form the EAE antigen emulsion. The Lewis rats were anesthetized via 10% chloral hydrate celiac injection (350 mg/kg). Subsequently, 0.4 ml antigen emulsion was injected into the rats in the EAE and TWP groups at two points on the footpad of each hindpaw, with the rats in the control group receiving PBS instead.

**Drug therapy.** TWP was dissolved in 10% glucose, which was fed to the rats in the TWP group at 10 mg/kg/day. The rats in the model and control group received an equal volume of 10% glucose daily for 21 days.

**Observation of symptoms and nerve function scores.** The activity and weights of the rats were examined daily. A five-point scoring method was used to evaluate the neurological function of the rats: 6, normal; 5, tail weakness; 4, hind leg complete paralysis with urinary incontinence; 3, bilateral posterior paresis (partial paralysis); 2, tail unrectal sensory loss; 1, tail unrectal sensory loss and muscle fasciculation; 0, moribund or dead. The mean score was obtained from the sum of the scores divided by the number of rats.

**Specimen collection.** In the EAE and TWP groups, the rats with neurological functions scores >4, or with continuation of symptoms for 3 days without aggravation, were considered to be the peak of EAE and the rats were sacrificed. The rats in the control group were sacrificed on day 21. Blood (1.5 ml) from the heart was collected and stored at -20°C. The brain and spinal cord were removed, fixed in 4% paraformaldehyde and embedded in paraffin at room temperature overnight. The parietal lobe of the brain, cerebellar brainstem, cervical enlargement and intumescence lumbalis were sectioned up to 1 cm³ for hematoxylin and eosin (H&E) staining.

**Pathological examination.** The numbers of lesions were counted under microscope (CX41; Olympus Corporation, Tokyo, Japan) following H&E staining. Elongated cells or the infiltration of >20 inflammatory cells were defined as an inflammatory focus. The parietal lobe of the brain, cerebellum brainstem, cervical enlargement and intumescence lumbalis from each rat were examined. The numbers of lesions in five sections from each region were calculated and combined as the number of inflammatory foci in the rat.

**TUNEL assay.** The first lumbar spinal cord tissue sections from the TWP group and EAE group were dewaxed and hydrated. Following the addition of proteinase K solution (20 μg/ml), TUNEL reaction mixture (25 μl), Counter-AP solution (50 μl) and NBT/BCIP (50-100 μl) were added, and the section was stained again in nuclear fast red. The section was observed following sealing and drying. A total of 5 visual fields containing sleeve-type changes were selected for the calculation of inflammatory cell infiltration around the blood vessel. Nuclei stained black indicated apoptotic cells. The apoptotic rate of the infiltrated inflammatory cells was calculated as the number of apoptotic cells/number of infiltrated inflammatory cells, with data presented as the mean ± standard error of mean.

**ELISA.** The rat IL-2 ELISA kit (K4800-100) was purchased from Guangrui Bio (Abnova). Briefly, the plasma samples from rats were added into the microplate pre-coated with IL-2-capture antibody and incubated at 36°C for 90 min. Following washing with PBS, the plate was filled with biotinylated anti-IL-2 polyclonal antibody (KA0276; 1:100; Abnova) at 37°C for 60 min. Subsequently, avidin-biotin-peroxidase complex working liquid was added at 37°C for 30 min. Finally, 3,3',5'-tetramethyl benzidine (TMB) was added at 37°C in the dark for 20 min. Following the addition of TMB stop buffer, the plate was read on a microplate reader at 450 nm to calculate the IL-2 concentration.

**Immunohistochemistry.** The paraffin sections were dewaxed and dehydrated. They were then treated with 3% H₂O₂ for 10 min. Following the addition of citrate buffer solution, microwave antigen repair and non-immune serum antigen blocking for 20 min, the sections were treated with anti-NF-kB p65 antibody (cat. no. 8242T; 1:200) at 4°C overnight. The section was then incubated in biotin IgG antibody (cat. no. ab6720; 1:200) at 37°C for 60 min. Subsequently, avidin-biotin-peroxidase complex working liquid was added at 37°C for 30 min. Finally, 3,3',5'-tetramethyl benzidine (TMB) was added at 37°C in the dark for 20 min. Following the addition of TMB stop buffer, the plate was read on a microplate reader at 450 nm to calculate the IL-2 concentration.
Results

Clinical morbidity rates. In the EAE group, all rats were unwell following feeding with MBP for 10-12 days, with a morbidity rate of 100%. The clinical manifestations included depression, anorexia, hair loss, tail-dragging and weight loss. The data obtained from pathological examination revealed that a large number of inflammatory cells around the blood vessels exhibited cuffing infiltration (Fig. 1). The peak period was 2 days following feeding, with symptoms of hind-limb paralysis and rats exhibiting gatism or an agonal state. The highest symptom score in the model group reached 3.36±0.64, whereas no symptoms were observed in the control group. Clinical changes in the TWP group appeared on days 13-16 and the morbidity rate was 60%. The rats exhibited mild symptoms, and the highest score was 2.10±0.43 (Fig. 2). Of note, in addition to the different incidence rates between the EAE and TWP group, the highest average neurological function score, average time of onset and number of lesions were statistically different between the two groups (P<0.05; Table I). Numerous inflammatory lesions were identified in the brain and spinal cord, and there was increased monocyte and lymphocyte infiltration around the blood vessels with sleeve-like changes. Gliocyte proliferation resulting in the formation of glial nodules was found in the brain and spinal cord white matter. The number of lesions in the TWP group was significantly lower, compared with the number in the EAE group (P<0.05; Table I). No abnormalities were observed on pathological examination of the control group.

TUNEL detection. The number of TUNEL-positive cells increased significantly in the CNS following the onset of EAE. As demonstrated in Table II, the apoptotic rate of the inflammatory cells around the blood vessels in the TWP group was 32.5%, compared with 16.5% in the EAE group (P<0.01). This suggested that TWP induced the apoptosis of cells in the CNS inflammatory infiltrate. A reduced number of inflammatory infiltrate cells were apparent in the TWP group, compared with that in the EAE group (P<0.01; Table II), indicating TWP had a promoting effect on the apoptosis of inflammatory infiltrate cells (Fig. 3).

Effect of TWP on the serum expression of IL-2 in EAE. Compared with the control, serum levels of IL-2 were increased significantly in the EAE and TWP groups. The TWP group exhibited a significantly lower serum level of IL-2, compared with that in the EAE group (P<0.05; Table III), suggesting that TWP suppressed the serum level of IL-2 level in the acute stage of EAE.

Effect of TWP on the expression of NF-κB p65 in the EAE CNS. A small number of NF-κB-P65 positive cells appeared in the CNS in the control group, which were mainly nerve cells and glial cells. A large number of NF-κB-P65-positive cells were found in the CNS of the EAE group, and these were mainly located in the white matter, particularly around the blood vessels, in a diffuse distribution. NF-κB p65-positive cells were stained dark blue with reduced cytoplasm.

![Figure 1. Cuffing infiltration of inflammatory cells around blood vessels. The small arrow points to macrophages with large, kidney-shaped nuclei. The large arrow points to lymphocytes with small, round nuclei stained dark blue with reduced cytoplasm.](image1)

![Figure 2. Daily clinical scores following feeding with TWP. EAE, experimental autoimmune encephalomyelitis; TWP, Tripterygium wilfordii glycoside.](image2)
cells were also found in the TWP group, however, the number was significantly lower, compared with that in the EAE group (P<0.05; Fig. 4; Table III). This indicated that TWP inhibited the expression of NF-κB p65 in the CNS in EAE.

Discussion

MS is a form of demyelinating disease in the nervous system, which readily relapses. In patients with MS, 10-15% are disabled due to its rapid progress and they can succumb to mortality (7). Therefore, the identification and development
of an effective drug to weaken or terminate this process is a focus of investigations. EAE is widely used to investigate the pathogenesis of autoimmune disease and in the evaluation of immunosuppressive drugs (8). T cell activation and proliferation are key processes in the immune response. The suppression of T cell activation and proliferation is important in the treatment of EAE (9). NF-κB is a DNA binding protein, which binds with specific regions of several gene promoters or enhancers, and is involved in the regulation of multiple genes, including cytokines and adhesion molecules closely associated with immune inflammation (10). In addition, NF-κB is important in immune cell proliferation, activation and apoptosis. The regulation of NF-κB activity directly affects the immune status of the body (11). *Tripterygium wilfordii* has been commonly used in clinical anti-inflammatory and immunosuppressive treatments in previous years. Experimental and clinical data have confirmed that *Tripterygium wilfordii* inhibits the immune response at several levels (12).

In the present study, TWP treatment significantly reduced the morbidity (Table I) compared with that in the EAE group, and prolonged the incubation period of Lewis rats in the EAE group. TWP decreased weight loss and alleviated clinical symptoms, suggesting that it had a therapeutic effect on EAE. Cell apoptosis is form of autonomous cell death, which is controlled by genes. It facilitates the elimination of excessive activated T cells in the immune response and maintains stability. Early in the 1960s, apoptosis was observed in the course of EAE. Schmied et al. (13) confirmed that the cell death in EAE was apoptotic, based on morphological observation. The majority of apoptotic cells were activated T cells, with a number of macrophages and oligodendrocytes. As a human autoimmune disease similar to MS, spontaneous remission in EAE is closely associated with inflammatory cell apoptosis in the CNS. As T cells are important in regulating the immune response, treatments able to selectively inhibit T cell activation or induce T cell apoptosis have an immeasurable effect on autoimmune diseases (14). As mentioned previously, the effectiveness of *Tripterygium wilfordii* in the treatment of autoimmune diseases, including rheumatoid arthritis, nephropathy and lupus erythematosus, has been confirmed by a number of clinical and experimental studies. It has been found to induce the apoptosis of activated T cells (15). In the present study, it was found that TWP effectively inhibited the progression of EAE, and it was hypothesized that TWP protects against the disease by promoting the apoptosis of cells in the CNS inflammatory infiltrate to prohibit the unlimited accumulation of inflammatory cells, as shown in a previous study (16). In the EAE model, typical symptoms were usually observed 3 days following onset. Therefore, the animals were anesthetized 3 days following the appearance of clinical symptoms, or were immediately sacrificed if in an agonal state. Between the onset of EAE and the observation of severe clinical symptoms, a large number of T cells and macrophages moved through the blood brain barrier, gathered in the region around the meninges and blood vessels, and entered the CNS parenchyma. This inflammatory infiltration was parallel with the severity of EAE symptoms, which was inconsistent with a previous finding that the ratio of infiltrated cells and apoptotic cells contributed to the direction of disease (17). EAE was characterized by inflammatory cells around the vessels, which were gathered in a sleeve-type appearance and recognizable under light microscopy. The infiltrated cells consisted mainly of T cells, macrophages and a small number of microglial cells, therefore, inflammatory cells around the blood vessels in the CNS were examined to investigate the entire CNS inflammatory infiltration. In a previous study, it was reported that EAE lesions were most severe in the lumbosacral segment, and were parallel with the severity of EAE symptoms and course of disease (18). Therefore, the spinal cord at the first waist section was selected for observation in the present study. It was found that the number of perivascular inflammatory infiltrate cells was significantly lower in the TWP group, compared with that in the EAE group, and the TUNEL-positive cell percentage was 35.5% in the TWP group, compared with 16.5% in the EAE group.

The application of NF-κB-suppressing drugs for anti-inflammatory effects has been a focus of investigation (19). It has been reported that triptolide is a potent NF-κB inhibitor (20). The present study successfully established an MS animal model of EAE through the treatment of Lewis rats with MBP to overcome the disadvantages of poor repeatability and instability of guinea pig spinal cord homogenate sensitization (21). The experiment showed that the expression of NF-κB p65 in the CNS was significantly elevated in the acute stage of the EAE group, and the location of NF-κB p65-positive cells was in accordance with the distribution of inflammatory lesions. This suggested that the activation of NF-κB in the CNS was important in the pathogenesis of EAE. The positive expression of NF-κB p65 in the CNS decreased significantly following TWP intervention (P<0.05). ELISA detection showed that the serum level of IL-2 increased 100.03% in the acute phase of EAE, compared with the normal control, indicating that IL-2 is important in acute EAE. By contrast, TWP reduced the serum level of IL-2 in the fastigium by 33.72%, compared with that in the model group. Based on these results, it was hypothesized that the possible mechanism underlying the effect of TWP in the treatment of EAE was as follows: Under the circumstances of infection, trauma, ischemia or hypoxia stimulation, NF-κB in endothelial cells, neurons and glial cells is activated; activated NF-κB translocates into the nucleus and binds with NF-κB loci on target genes, promoting the elevation of proinflammatory cytokine IL-2. This causes damage to the blood brain barrier. Inflammatory cells and cytokines, including IL-2, enter the CNS and activate the immune cells within the CNS expressing NF-κB, which exacerbates the inflammation and demyelination. TWP inhibits the activation of NF-κB and regulates the expression and activation of inflammatory medium. This reduces the inflammatory effect of TH1 cytokines, including IL-2. TWP also suppresses the proliferation and recruitment of activated lymphocytes in the CNS through CNS inflammatory infiltrate cell apoptosis, which cuts off a series of inflammatory processes to inhibit EAE lesions and relieve the progression. As a mature proprietary Chinese medicine, TWP is low cost and causes fewer adverse reactions. TWP may have a potential effect in nervous system immune disease.

In conclusion, the present study showed that TWP suppressed EAE by inhibiting CNS inflammatory cell infiltration, upregulating apoptosis, and reducing the levels of NF-κB and IL-2.
Acknowledgements

This study was supported by the Natural Science Foundation of Fujian Province (grant no. 2008J0308).

References


